peptide glp-1 Glucagon-Like 1 | C149H226N40O45 | CID 16133831 rated GLP GLP-1 Drugs and the Physiology

Clinical trial data show average weight loss of approximately 10 to 15 percent of starting body weight by six months for patients on maintenance doses of semaglutide or tirzepatide

Image Credit: Love Employee / Shutterstock In a recent study published in the International Journal of Obesity , researchers assessed the effects of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists on weight and body composition in adults with overweight or obesity

This would be consistent with other research on the impact of GLP-1 drugs for obesity on medical budgets: Institute for Clinical and Economic Review (ICER) 2022: Lifetime cost of drugs $274K

Weight loss on the Wegovy Pill is comparable between the pill and the injection

If a patient needs to change their weekly injection day, the FDA label advises ensuring at least 3 days between doses

FDA approval applies to those specific finished, brand-name drug formulations and their approved indications it does not extend to compounded semaglutide prepared by third-party pharmacies